Pfizer Earnings Call Highlights Growth Beyond COVID

Pfizer Inc ((PFE)) has held its Q1 earnings call. Read on for the main highlights of the call.

Pfizer’s latest earnings call struck a notably upbeat tone, as management highlighted a clean revenue and EPS beat, broad-based growth outside COVID and visible momentum in newer products. Executives acknowledged near-term pressures from loss-of-exclusivity, royalty costs and heavier R&D spend, but argued these are manageable against a strengthening pipeline and clearer long-term cash-flow outlook.

Revenue Beat Underscores Solid Start to 2026

Pfizer reported Q1 2026 revenues of $14.5 billion, a 2% operational increase that topped expectations and showed resilience despite COVID headwinds. Reported diluted EPS came in at $0.47 and adjusted diluted EPS at $0.75, both ahead of consensus, reinforcing confidence in management’s execution against its reset post-pandemic baseline.

Core Business Strength Excluding COVID Products

Beneath headline numbers, the non-COVID portfolio continued to accelerate, with ex-COVID revenues growing about 7% operationally in the quarter. Management framed this as evidence of broad demand across key franchises and a validation of recent portfolio reshaping as COVID-related sales normalize to more modest, seasonal levels.

New Launches and Acquisitions Drive Growth Engine

Launched and acquired products were a major growth engine, generating $3.1 billion in Q1 revenue and growing roughly 22% operationally. Standout contributors included Nurtec, which surged 41% operationally, and oncology assets from Seagen, which posted 20% operational growth year over year, supporting the company’s diversification beyond legacy blockbusters.

Pipeline Wins Highlight Clinical and R&D Progress

R&D momentum was another bright spot, with three positive Phase III readouts and encouraging mid-stage data early in 2026. Key highlights included Padcev plus pembrolizumab cutting risk of recurrence or death by nearly half in cisplatin-eligible bladder cancer and MagnetisMM-5 for Elrexfio showing strong progression-free survival benefits in multiple myeloma.

Legal Outcomes Strengthen Long-Term Cash-Flow Profile

Settlements around Vyndamax patents and a favorable Belgian court ruling tied to Comirnaty contracts have sharpened visibility into post-2028 cash flows and earnings power. Management now sees entering a five-year stretch of high single-digit revenue CAGR from 2029, with projected loss-of-exclusivity exposure trimmed to about $14–15 billion from roughly $17 billion previously.

Vaccine Franchise and Pipeline Push for Future Leadership

Pfizer also underscored its ambition to sustain vaccine leadership with meaningful pipeline moves. The company kicked off a Phase III trial for a 25-valent pediatric pneumococcal candidate and is advancing a fifth-generation adult vaccine covering 35 serotypes into clinical development this year, aiming to defend and expand its pneumococcal stronghold.

Cost Savings, Margins and Balanced Capital Allocation

Adjusted gross margin held around 76% in Q1, consistent with guidance for the mid-70s range, as cost-savings programs began to bite. Phase I of manufacturing optimization is expected to deliver about $700 million in 2026 savings, with approximately $175 million realized in Q1, while total net savings of $7.2 billion are targeted by end-2026.

Investment, Deleveraging and Deal Capacity in Focus

On capital allocation, Pfizer invested $2.5 billion in internal R&D and returned $2.4 billion to shareholders via dividends in Q1, while keeping leverage near 2.8x. The company also monetized its ViiV stake for roughly $1.65 billion in net proceeds and cited around $7 billion of business-development capacity, supported by operating cash flow of $2.6 billion in the quarter.

Persistent LOE Headwinds Through 2028

Despite positive legal developments, management reiterated that loss-of-exclusivity pressures will remain a multi-billion-dollar headwind through 2028. Leverage may hover around or slightly above current levels during this transition, underscoring the need for disciplined capital deployment as the company works to offset erosion from aging products.

COVID Seasonality and Paxlovid Drag on Near Term

The COVID franchise remains a swing factor, with subdued disease levels expected to keep Paxlovid utilization depressed in the near term. Comirnaty sales are now heavily seasonal and back-loaded, with most 2026 revenue anticipated later in the year, which management cited as a reason for not lifting full-year guidance despite a strong first quarter.

Margin Pressure from Royalty and R&D Spend

Gross margin, while solid, was dampened versus last year by higher accrued royalty expenses, revealing some cost pressure beneath the surface. At the same time, adjusted R&D spending rose 11% operationally as Pfizer ramps investment in oncology and obesity pipelines, adding to near-term expense burdens in pursuit of longer-term growth.

Operating Expense Growth and Cash Outflows

Total adjusted operating expenses reached $5.5 billion, up 4% operationally, reflecting the push behind new launches and pipeline programs. Management also flagged a sizeable $2.6 billion tax payment made in April and reiterated that leverage near 2.8x constrains room for large-scale buybacks in the immediate term.

Comirnaty Volatility Linked to Contract Timing

Q1 Comirnaty revenues declined in part due to the absence of prior-year shipments tied to a U.K. contract, a timing effect rather than a sharp drop in underlying vaccine demand. Even so, this contract-driven volatility highlights how COVID revenues can swing quarter to quarter, complicating near-term forecasting despite a more stable seasonal pattern emerging.

Guidance and Long-Term Outlook Remain Intact

Pfizer reaffirmed its 2026 outlook for total revenues of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, anchored by mid-70s adjusted gross margins and a 38% adjusted operating margin in Q1. Management backed this confidence with ongoing cost-discipline targets, robust Q1 performance in launches and acquisitions and a longer-term view of entering a high single-digit revenue growth phase starting in 2029.

Pfizer’s earnings call painted a picture of a company navigating post-pandemic normalization while building a more durable growth mix anchored in oncology, vaccines and acquired assets. For investors, the message was one of solid execution and improving long-term visibility, even as COVID seasonality, LOEs and elevated spending keep the near-term path bumpy but manageable.